Pacer Advisors
CRSP icon

Pacer Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Pacer Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51K Buy
+932
New +$49.1K ﹤0.01% 2035
2024
Q3 		– Sell
-1,038
Closed -$56.1K – 2594
2024
Q2 		$56.1K Buy
1,038
+500
+93% +$28.9K ﹤0.01% 3075
2024
Q1 		$36.7K Buy
+538
New +$38.5K ﹤0.01% 3297

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pacer Advisors's CRSP Position: Q2 2026 in Review

Pacer Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 932 shares worth $51K. The stake represents ﹤0.01% of the portfolio and ranks #2035 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in CRSP as recently as Q2 2024.

Pacer Advisors first reported a position in CRSP in Q1 2024 and has held it in 3 quarters since. The position peaked at $56.1K in Q2 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Pacer Advisors held 932 shares of CRISPR Therapeutics worth $51K as of Q2 2026.
  • CRISPR Therapeutics was a new Pacer Advisors position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2035 holding.
  • Pacer Advisors first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Pacer Advisors's CRISPR Therapeutics position peaked at $56.1K in Q2 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.